Amino-imidazolones for the inhibition of beta-secretase
申请人:Malamas Sotirios Michael
公开号:US20060160828A1
公开(公告)日:2006-07-20
The present invention provides an amino-imidazolone compound of formula I
Also provided are compositions and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.
Access to Cyclic Amino Boronates via Rhodium-Catalyzed Functionalization of Alkyl MIDA Boronates
作者:Jeffrey D. St. Denis、C. Frank Lee、Andrei K. Yudin
DOI:10.1021/acs.orglett.5b02861
日期:2015.12.4
sulfamate esters derived from amphoteric α-boryl aldehydes. Depending on the substitution pattern of the boryl sulfamate ester, a diverse range of five- or six-membered ring heterocycles are accessible using this transformation. The highly chemoselective nature of the C–H functionalization reaction preserves the alkyl boronate functional group, which enables the synthesis of B–C–N and B–C–C–N motifs
Using the previously designed biphenyl‐2‐ylphosphine ligand, featuring a remote tertiary amino group, the first gold‐catalyzed intermolecular hydroalkenylation of alkynes has been developed. Synthetically valuable conjugated dienyl alcohols are formed in moderate to good yields. A range of alkenyltrifluoroborates are allowed as the alkenyl donor, and no erosion of alkene geometry and/or the propargylic
This invention relates to novel compounds having the structural formula I below:
and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.